Participants 161 271 4
Breakthrough cancer pain (BTcP) represents an important clinical challenge in the care of patients with cancer
Participants 419 463 3
BTcP in opioid-tolerant patients with cancer
Participants 493 653 5
This was a randomized, placebo-controlled, multi-center, phase III trial, conducted in opioid-tolerant male and female patients (aged > or =17 years) with BTcP.
Participants 1412 1511 5
131 patients entered the titration phase, of whom 61 were included in the primary efficacy analysis
Participants 2546 2582 3
opioid-tolerant patients with cancer
